← Back to Analyst Consensus 
BIOA Buy
BioAge Labs, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | UBS | initiate | — → Neutral | — | 54% |
| Sep 9, 2026 | Roth Capital | reiterate | Buy → Buy | — | 53% |
| Sep 8, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Aug 6, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Aug 3, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jul 31, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| May 27, 2026 | Roth Capital | initiate | — → Buy | — | 53% |
| May 13, 2026 | BTIG | initiate | — → Buy | — | 52% |
| Mar 27, 2026 | Needham | initiate | — → Buy | — | 50% |
| Mar 10, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Feb 25, 2026 | Oppenheimer | initiate | — → Outperform | $60 | 52% |
| Feb 18, 2026 | Jefferies | upgrade | Hold → Buy | $62 | 52% |
| Jan 27, 2026 | Piper Sandler | initiate | — → Overweight | $73 | 54% |
| Dec 8, 2025 | Morgan Stanley | upgrade | Underweight → Equal-Weight | $12 | 54% |
| Oct 29, 2025 | Citigroup | maintain | Buy → Buy | $15 | 54% |
| Oct 22, 2025 | Citigroup | upgrade | Neutral → Buy | $10 | 54% |
| Mar 24, 2025 | Citigroup | maintain | Neutral → Neutral | $5 | 54% |
| Feb 28, 2025 | William Blair | initiate | — → Market Perform | $0 | 48% |
| Dec 9, 2024 | Citigroup | downgrade | Buy → Neutral | $7 | 54% |
| Dec 9, 2024 | Jefferies | downgrade | Buy → Hold | $7 | 52% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days